Unfit individuals also have the alternative of venetoclax furthermore obinutuzumab (VO) as frontline therapy. This is based over a section III trial that in comparison VO with ClbO in aged/unfit individuals.113 VO was excellent when it comes to reaction rate and progression-cost-free survival, and experienced a similar protection profile. During https://camillaa864rzh1.blog-eye.com/profile